B2B SaaS Provider · vs · B2B SaaS Provider
CGI vs Tietoevry
Structured technology and market comparison · 2026
Direct Feature Comparison
CGI · vs · TietoevryEnterprise consulting and vertical software provider for regulated industries.
Nordic enterprise software and IT services provider.
Analyze all overlapping signals and tech stacks for CGI and Tietoevry
Compare mutual enterprise clients, monetization models, live market signals, and partner networks directly in the interactive Knowledge Graph.
Comparison Analysis
What is the main difference between CGI and Tietoevry?
When comparing CGI and Tietoevry, both platforms operate within the B2B SaaS Provider ecosystem. CGI is positioned as Enterprise consulting and vertical software provider for regulated industries, whereas Tietoevry focuses on Nordic enterprise software and IT services provider. Decision-makers evaluate both solutions when orchestrating their commercial monetization and technology stack.
What are the top alternatives to CGI and Tietoevry?
When evaluating CGI and Tietoevry, enterprise buyers also consider other platforms in B2B SaaS Provider. You can discover the full competitive landscape and evaluate other alternatives by viewing their respective footprint profiles on Polaris7.
Market Signals
Recent Market Signals & Activity: CGI vs Tietoevry
Documented market movements, strategic partnerships, product releases, and regulatory developments mapped across Polaris7.
CGI
Recent Signals
- ·CGI
CGI named a Leader in the 2026 IDC MarketScape vendor assessment of worldwide trade finance systems
CGI has been named a Leader in the 2026 IDC MarketScape vendor assessment of worldwide trade finance systems, a significant industry recognition for the company's trade finance technology leadership.
- ·SEC APIfinancials
10-Q Financial Filing Analysis for CGI (2026-07-29)
Corcept Therapeutics reported strong financial results for the second quarter ended June 30, 2026, generating net product revenue of $256.1 million, a 31.7% increase year-over-year. Growth was accelerated by the commercial launch of Lifyorli (relacorilant) in combination with nab-paclitaxel for platinum-resistant ovarian cancer, which contributed $47.6 million in debut quarterly sales alongside core hypercortisolism therapies. On the regulatory and legal front, Corcept resubmitted its relacorilant NDA for endogenous Cushing's syndrome with a PDUFA date set for December 17, 2026, while the Court of Appeals affirmed a non-infringement ruling in the Teva patent litigation and denied a rehearing en banc in July 2026.
- Q2 2026 net product revenue rose 31.7% year-over-year to $256.1 million, bolstered by $47.6 million in initial sales from newly launched Lifyorli.
- Corcept resubmitted its New Drug Application (NDA) for relacorilant in endogenous Cushing's syndrome on June 17, 2026, establishing an FDA PDUFA target action date of December 17, 2026.
- The Court of Appeals affirmed a District Court ruling of non-infringement in the Teva patent litigation, with a petition for rehearing en banc denied in July 2026.
- ·PR Newswire: Advertising & MarketingFinancials
CGI Prices C$500 Million Senior Notes Offering
CGI Inc. has priced a private offering of C$500 million in senior unsecured notes, split equally between 3.25-year and 4.75-year maturities, with interest rates of 4.195% and 4.484% respectively. The offering is expected to close around September 14, 2026, and the net proceeds of approximately C$497.3 million will be used to repay existing indebtedness and for general corporate purposes. The notes are being offered in Canada on a private placement basis through a syndicate of agents led by major Canadian financial institutions including Scotiabank, Desjardins, BMO, CIBC, National Bank, RBC, and TD Securities. This financing move is part of CGI's capital management strategy to optimize its debt structure, reflecting the company's strong market position and liquidity management.
- CGI priced C$500 million in senior unsecured notes, split into two series of C$250 million each.
- The notes carry interest rates of 4.195% (3.25-year) and 4.484% (4.75-year).
- Net proceeds of ~C$497.3 million will be used for debt repayment and general corporate purposes.
Tietoevry
Recent Signals
No recent market signals documented for Tietoevry in the current tracking window.
Compare their exact ecosystem overlaps.
Explore all deep relationships in Polaris7. Discover exactly which mutual clients, integrated technologies, and overlapping partners CGI and Tietoevry share across the market ecosystem.